Abstract
Virus-induced asthma exacerbation is a health burden worldwide and lacks effective treatment. To better understand the disease pathogenesis and find novel therapeutic targets, we established a mouse model of steroid (dexamethasone (DEX)) resistant asthma exacerbation using ovalbumin (OVA) and influenza virus (FLU) infection. Using liquid chromatography-tandem mass spectrometry (LC-MC/MS), we performed a shotgun proteomics assay coupled with label-free quantification to define all dysregulated proteins in the lung proteome of asthmatic mice. Compared to control, 71, 89, and 30 proteins were found significantly upregulated by at least two-fold (p-value ≤ 0.05) in OVA-, OVA/FLU-, and OVA/FLU/DEX-treated mice, respectively. We then applied a Z-score transformed hierarchical clustering analysis and Ingenuity Pathway Analysis (IPA) to highlight the key inflammation pathways underlying the disease. Within all these upregulated proteins, 64 proteins were uniquely highly expressed in OVA/FLU mice compared to OVA mice; and 11 proteins were DEX-refractory. IPA assay revealed two of the most enriched pathways associated with these over-expressed protein clusters were those associated with MHC class I (MHC-I) antigen-presentation and interferon (IFN) signaling. Within these pathways, signal-transducer-and-activator-of-transcription-1 (STAT1) protein was identified as the most significantly changed protein contributing to the pathogenesis of exacerbation and the underlying steroid resistance based on the label-free quantification; and this was further confirmed by both Parallel Reaction Monitoring (PRM) proteomics assay and western blots. Further, the pharmacological drug Fludarabine decreased STAT1 expression, restored the responsiveness of OVA/FLU mice to DEX and markedly suppressed disease severity. Taken together, this study describes the proteomic profile underpinning molecular mechanisms of FLU-induced asthma exacerbation and identifies STAT1 as a potential therapeutic target, more importantly, we provided a novel therapeutic strategy that may be clinically translated into practice.
Highlights
Asthma is a chronic inflammatory airway disorder, characterized by wheezing, shortness of breath, coughing, and tightness of the chest [1]
Mice treated with OVA alongside influenza virus (FLU) infection (OVA/FLU) exhibited dramatically exacerbated airway hyper-responsiveness (AHR) compared to OVA alone or the control phosphate-buffered saline (PBS)/FLU group (Figure 1B)
We identified the important roles of MHC class I (MHC-I) antigen presenting and IFN-STAT1 signaling pathways in triggering asthma exacerbation
Summary
Asthma is a chronic inflammatory airway disorder, characterized by wheezing, shortness of breath, coughing, and tightness of the chest [1]. Asthma exacerbation is an acute worsening of normal asthma symptoms, which significantly decreases patients’ quality-of-life and remains as a major cause of disease mortality in patients [2]. The socioeconomic cost of asthma exacerbation is a significant healthcare burden globally [3]. The most common triggers of asthma exacerbation are respiratory viral infections [4]. Rhinovirus (RV) and respiratory syncytial virus (RSV) are two of the most common viral pathogens causing asthma exacerbation [4]. Influenza virus (FLU)-induced asthma exacerbation occurs less frequently, it is more refractory due to a poorer response to current mainstay treatments (i.e steroid therapy) compared to RSV and RV [6]. Effective clinical management of viral induced steroid-resistant asthma exacerbation remains a significant unmet need. There is an urgent need for the development of innovative therapeutic strategies to treat asthma exacerbation, especially during those linked to FLU seasons and/or influenza pandemics
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
